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ABSTRACT
Purpose The Applied Public- Private Research enabling 
OsteoArthritis Clinical Headway (APPROACH) consortium 
intends to prospectively describe in detail, preselected 
patients with knee osteoarthritis (OA), using conventional 
and novel clinical, imaging, and biochemical markers, to 
support OA drug development.
Participants APPROACH is a prospective cohort study 
including 297 patients with tibiofemoral OA, according to the 
American College of Rheumatology classification criteria. 
Patients were (pre)selected from existing cohorts using 
machine learning models, developed on data from the CHECK 
cohort, to display a high likelihood of radiographic joint space 
width (JSW) loss and/or knee pain progression.
Findings to date Selection appeared logistically feasible 
and baseline characteristics of the cohort demonstrated an 
OA population with more severe disease: age 66.5 (SD 7.1) 
vs 68.1 (7.7) years, min- JSW 2.5 (1.3) vs 2.1 (1.0) mm 
and Knee injury and Osteoarthritis Outcome Score pain 
31.3 (19.7) vs 17.7 (14.6), except for age, all: p<0.001, 
for selected versus excluded patients, respectively. Based 
on the selection model, this cohort has a predicted higher 
chance of progression.
Future plans Patients will visit the hospital again at 6, 12 
and 24 months for physical examination, pain and general 
health questionnaires, collection of blood and urine, MRI 
scans, radiographs of knees and hands, CT scan of the 
knee, low radiation whole- body CT, HandScan, motion 
analysis and performance- based tests.
After two years, data will show whether those patients 
with the highest probabilities for progression experienced 
disease progression as compared to those wit lower 
probabilities (model validation) and whether phenotypes/
endotypes can be identified and predicted to facilitate 
targeted drug therapy.
Trial registration number NCT03883568
Strengths and limitations of this study
 ► The Applied Public- Private Research enabling 
OsteoArthritis Clinical Headway (APPROACH) cohort 
is part of a larger consortium, bringing together a 
highly qualified and multidisciplinary group of stake-
holders in the form of a public–private partnership 
of engaged, knowledgeable and complementary in-
dustrial, academics and patient experts.
 ► The APPROACH cohort is unique in its selection pro-
cess, recruiting patients from existing cohorts based 
on machine learning models with encouraging re-
sults of which the actual utility needs to be demon-
strated at the end of the 2- year follow- up.
 ► The APPROACH cohort will provide 2- year follow- 
up data of 297 knee osteoarthritis patients includ-
ing conventional and novel, explorative, imaging, 
biochemical, clinical and demographic (bio)mark-
ers according to strict protocols for acquisition 
and evaluation with the aim to identify phenotypes 
and develop predictive models for progression of 
these phenotypes.
 ► The main limitations of the study are the descriptive 
phase in which the study is at present and the still 
limited number of 297 patients related to the large 
number of outcome parameters.
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INTRODUCTION
Osteoarthritis (OA) is characterised by changes in all 
(peri)articular tissues,1 2 causing pain, stiffness and loss 
of function, usually following a slowly progressive and 
nonlinear course.2 OA of the knee is the most common and 
most disabling, accounting for 83% of total OA burden.3 
In 2010, the global prevalence of knee OA was estimated 
to be 4.7% in females and 2.6% in males and incidence 
peaked around the age of 50.4 Knee OA accounted at that 
time for 14.218 of total years lived with disability. This is a 
64.8% increase compared with 1990 (8.627), emphasising 
the increasing burden of OA.3 Estimated healthcare 
costs of knee OA are €4.257 (€383–€7.675) per patient 
per year. Non- healthcare- related costs of knee OA, like 
productivity loss, are estimated to be €1.519 per patient 
per year.5 Ageing of the population, an increasing active 
life style at older age, and the current obesity pandemic 
all contribute to an even further increase of the incidence 
and prevalence of OA and its societal burden.6
Despite this growing OA burden and the still unmet 
need for effective treatment, pharmaceutical companies 
seem to have lost their confidence in drug development 
because clinical trials with potential disease- modifying 
OA drugs (DMOADs) could not demonstrate efficacy. 
This disappointing result likely has multiple origins.
The typically slow and heterogeneous OA course makes 
trials easily fall short in terms of size and length for 
demonstrating treatment efficacy.7 This issue is further 
aggravated by the use of relatively insensitive outcome 
measures (patient- reported outcome measurements), 
pain and radiographic joint space changes (X- ray), 
required by regulatory agencies for a drug to be certified 
as a DMOAD. Moreover, an incomplete understanding of 
the OA pathobiology obscures identification of proper 
treatment targets. This is complicated by the increasing 
knowledge that the pathobiological mechanisms driving 
the OA process differ between patients, (type of) joints 
and disease stages.2
This to- date concept of a highly heterogeneous disease 
contrasts with the one- size- fits- all treatment approach 
used in most trials and the focus on radiographic joint 
space narrowing (JSN) and pain as outcome parameters.
New (combinations of) sensitive and robust (bio)
markers could importantly contribute to overcome the 
aforementioned challenges, improving the design of 
clinical trials in the OA field. Biomarkers with the ability 
to predict the likely disease course in an untreated indi-
vidual, viz. prognostic markers, could be employed to 
identify subjects that will show significant progression of 
the disease on relevant outcome parameter(s) over the 
study period. Biomarkers that show a biological response 
to treatment, response markers, could serve as sensitive 
outcome parameters, supplementing (or even replacing) 
radiographic joint space changes and MRI read- outs. 
These biomarkers could also help to identify vital compo-
nents of the OA pathobiology and with that distinguish 
between phenotypes/endotypes. This will help to forecast 
the potential response to treatments targeted to specific 
mechanisms. Altogether, such biomarkers could impor-
tantly improve the quality and effectiveness of trials of 
potential DMOADs and joint preserving surgical treat-
ments, in terms of selection of study participants, outcome 
parameters, and study size and length.8
Applied Public-Private Research enabling OsteoArthritis 
Clinical Headway
Although currently available cohort studies, like the Dutch 
CHECK9 and the US OAI with the FNIH10 have increased 
our knowledge of the disease, these attempts still have not 
resulted in clearly distinctive phenotypes/endotypes with 
predictive biomarkers. Therefore, the current Applied 
Public- Private Research enabling OsteoArthritis Clinical 
Headway (APPROACH) cohort uses a novel strategy and 
extends on previous studies in several ways. The study 
is part of a larger consortium being conducted under 
the Innovative Medicine’s Initiative, bringing together 
a highly qualified and multidisciplinary group of stake-
holders in the form of a public–private partnership of 
engaged, knowledgeable and complementary industrial, 
academic, and patient experts.
The APPROACH cohort is unique in its attempt to 
recruit patients primarily from existing cohorts using 
machine learning (ML) models (adjusted to the specific 
cohorts) trained using patient data from the CHECK 
cohort to increase the likelihood of radiographic joint 
space width (JSW) loss and/or knee pain progression 
during a limited, 2- year follow- up period. The relative 
short 2- year period is chosen to facilitate translation of 
results to pragmatic trial design.
In addition to this unique preselection of patients, 
the APPROACH cohort combines a very broad spec-
trum of conventional and novel, explorative, imaging, 
biochemical, clinical and demographic markers. Using 
data science techniques suitable to analyse these ‘big 
data’, algorithms of biomarkers will identify and predict 
phenotypes/endotypes of OA that share distinct under-
lying pathobiological mechanisms with their structural 
and function consequences, relevant for practical and 
targeted clinical trials.
The objectives of the cohort study are (https://www. 
approachproject. eu):
 ► To validate and refine the prediction model for 
sustained pain and decrease in (minimum) JSW as 
developed for the selection of patients.
 ► To develop and validate sensitive markers of/predic-
tive for OA progression by use of conventional and 
novel clinical, imaging, and biochemical (bio)
markers.
 ► To discover and predict novel OA phenotypes 
(eg, post- traumatic, metabolic, ageing, inflamma-
tory, bone driven and genetic) and (their) disease 
progression.
 ► To prospectively describe in detail the discovered 
phenotypes by use of conventional and novel clinical, 
imaging and biochemical (bio)markers.
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COHORT DESCRIPTION
The prospective follow- up of the 297 included patients 
will be 2 years. A large spectrum of conventional and 
novel (bio)markers for discovery (baseline, 1- year and 
2- year follow- up), and prediction (baseline and change 
over six months) of knee OA phenotypes/endotypes will 
be gathered.
Patient selection
Patients were stepwise selected for a high chance of 
structural progression (JSN) and/or pain progression/
sustained severity over two years, using two ML models, 
for the likelihood of each patient to be a ‘progressor’.
The selection process will be described in detail else-
where.11 In summary, patients with predominant tibiofem-
oral OA were selected from five European observational 
OA cohorts (CHECK,9 HOSTAS,12 MUST,13 PROCOAC14 
and DIGICOD; for cohort details see online supplemen-
tary file 1) using an ML approach, trained on longitu-
dinal data from the CHECK cohort, and adjusted for 
the specific cohorts using the available data from each 
of the cohorts. Separate models for prediction of struc-
tural progression and for sustained significant knee pain 
or pain progression were used. Structural progression was 
defined as a reduction in JSW of ≥0.3 mm per year over 
a period of 2–3 years (0.7 mm is the minimal detectable 
difference in radiographic JSW).15 Sustained significant 
pain and pain increase were defined as at least one of the 
three following: Knee injury and Osteoarthritis Outcome 
Score (KOOS) pain (on a 0–100 scale) increase ≥5/year 
and ≥40 at two years, KOOS pain increase ≥10/year and 
≥35 at two years or ≥40 at both baseline and two years. 
Three types of progression were defined: pain progres-
sion, structural progression, and both pain and structural 
progression.
All identified patients of the existing cohorts (ranking 
the highest for predicted progression in the first ML 
model) willing to participate were invited for a screening 
visit. During this visit, inclusion and exclusion criteria 
were checked and an index knee was selected based on 
American College of Rheumatology (ACR) criteria.16 
If both knees fulfilled the criteria, patients indicated 
their own index knee based on severity of complaints, 
in case equal the right knee was selected as the index 
knee. Key predictors from the first predictive ML model, 
for example, KOOS17 and Knee Image Digital Anal-
ysis (KIDA) parameters,18 were collected and fed into a 
subsequent predictive ML model that was uniform for 
all cohorts. The patients who ranked the highest in this 
second model were included and invited for a baseline 
visit.
Because the existing source cohorts could not all 
provide sufficient patients due to the selection process, 
patients withdrawing consent and non- compliance with 
inclusion criteria, a small number of additional patients 
were recruited from outpatient departments and invited 
for a screening visit (see figure 1). These newly recruited 
patients were also ranked and selected using the second, 
uniform predictive ML model.
Inclusion criteria
 ► Able to walk unassisted.
Figure 1 Flow diagram of patient selection for the APPROACH cohort study. APPROACH, Applied Public- Private Research 
Enabling OsteoArthritis Clinical Headway
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 ► ≥18 years of age.
 ► Capable of understanding the study.
 ► Capable of communicating in local language.
 ► Predominantly tibiofemoral knee OA and satisfying 
the clinical ACR classification criteria for knee OA:
 – Knee pain.
 – Three or more of the following:
 – >50 years of age.
 – <30 min of morning stiffness.
 – Crepitus on active motion.
 – Bony tenderness.
 – Bony enlargement.
 – No palpable warmth.
 ► High probability of progression (ranking) based on 
the algorithm using the following parameters:
 – Reduced version of KOOS questionnaire (pain, 
stiffness and function).
 – Body Mass Index.
 – Numeric Rating Scale (NRS) pain19 of index knee 
at moment of screening visit.
 – NRS pain of index knee in last week before screen-
ing visit.
 – Age.
 – Gender.
 – KIDA parameters of the index knee, based on 
standard weight- bearing radiograph, taken at 
screening.18
Exclusion criteria
 ► Inability to comply to the protocol.
 ► Participation in a trial of local therapeutic inter-
vention for index knee OA or potential systemic 
DMOADs at the time of inclusion, within six months 
before inclusion, and/or anticipated during two years 
of follow- up. Participation in non- interventional 
studies was allowed.
 ► Surgery of the index knee in the six months before 
inclusion and/or scheduled or expected surgery of 
the index knee during follow- up.
 ► Current pregnancy or planned pregnancy during 
follow- up (because of imaging).
 ► Predominantly patellofemoral knee OA.
 ► Secondary knee OA. For example, due to severe leg 
deformity (knee varus or valgus >10°), inflamma-
tory joint disease (either autoimmune, infectious or 
crystal- induced), severe chondrocalcinosis, Paget’s 
disease of the bone, ochronosis, acromegaly, haemo-
chromatosis, Wilson’s disease, osteochondritis disse-
cans, haemophilia.
 ► Alternative/additional causes of joint pain, for 
example, rheumatic symptoms due to malignancies, 
primary osteochondromatosis, osteonecrosis.
 ► Generalised pain syndrome, for example, fibromyalgia.
 ► Patients with contraindications for undergoing MRI 
or CT.
 ► Previous hip replacement or expected hip replace-
ment within six months.
 ► Osteosynthesis material near the knee joint.
 ► Self- reported severe spine OA.
 ► Current knee prosthesis; in case of surgical replacement 
of the index or contralateral knee during follow- up, 
images of that joint will be considered irrelevant and not 
be obtained. All other acquisitions will be performed as 
scheduled and patients will remain in the study.
Baseline characteristics of the APPROACH cohort
The baseline characteristics of the APPROACH cohort in 
total and per centre are shown in table 1.
Despite ranking of all screened patients from the 
different cohorts in one uniform ML model, baseline 
characteristics differed between the patients that were 
included from the different cohorts, representing the 
characteristics of the original source cohorts.
Investigation schedule
Conventional and novel clinical, imaging, biochemical 
and kinetic markers of the index knee and other joints 
were obtained at baseline and will be obtained at 6, 12 
and 24 months (table 2). For a detailed description of all 
parameters see online supplementary file 2.
Parameters for description of OA progression and phenotypes
OA progression and phenotype of the index knee over 
two years will be described by changes from baseline to 
the 1- year and/or 2- year visit.
The parameters used to define structural progression 
will be:
 ► Radiographic parameters of knee OA severity; 
JSW and osteophytes using KIDA measurements, 
Kellgren and Lawrence (KL) grading, and Osteo-
arthritis Research Society International (OARSI) 
grading.18 20 21
 ► Quantitative MRI parameters for cartilage including 
thickness, volume and denuded bone areas in the 
femorotibial joint.22
 ► Semi quantitative MRI scoring of cartilaginous and 
non- cartilaginous components including bone 
marrow oedema, meniscal alteration and synovitis, 
assessed separately and under a global score.23
 ► Advanced radiographic parameters; bone shape analyses 
and subchondral bone architecture on standard radio-
graphs and high- resolution CT representing OA related 
bone and trabecular deformations/adaptations.24
 ► (Bio)markers in blood and urine representing 
cartilage, bone and synovial matrix turnover and 
inflammation.
The parameters for pain and function will be:
 ► KOOS questionnaire.17
 ► Knee Intermittent and Constant OsteoArthritis Pain 
(ICOAP) questionnaire.25
 ► General pain and function parameters (eg, physical 
examination index knee).
Parameters for prediction of index knee OA progression and 
phenotypes
Prediction of OA progression (phenotype specific) will be 
evaluated using ML taking into account the parameters 
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mentioned above in addition to explorative markers at 
baseline and, if available, at 6 months:
 ► Qualitative MRI parameters; T2 relaxation MRI repre-
senting cartilage collagen distribution.26
 ► Advanced radiographic imaging parameters; bone 
shape analysis on MRI representing bone area and 
shape.27
 ► Motion analysis (GaitSmart28).
 ► Performance based tests (40m self- paced walk test and 
30s chair stand- up test).29
Covariables
Additionally, to the above- mentioned parameters, the 
following covariables are available for the ML modelling 
and analyses:
 ► Contralateral knee OA.
 – KIDA measurements,18 KL grading20 and OARSI 
grading.21
 ► Hand OA
 – Inflammation of hand joints (HandScan).30
 – OA features of hand joints on standard radiographs: 
KL grading,20 OARSI scoring21 and Verbruggen- 
Veys grading.31
 – Functional Index for Hand Osteoarthritis 
questionnaire.32
 ► Hip OA
 – OA features of the hips: Whole Body Low Dose CT 
(WBLDCT).33
 – Hip disability and Osteoarthritis Outcome Score34 
and hip ICOAP.25
 ► Facet joint OA and intervertebral disc degeneration: 
WBLDCT.
 ► OA features of glenohumeral and acromioclavicular 
joints: WBLDCT.
 ► General pain and function parameters
 – Short Form 36 questionnaire for quality of life.35
 – Pain with concomitant pain medication registra-
tion in a custom made 1- month pain diary.
 – Pain NRS of contralateral knee, both hips, both 
hands and spine.19
 – PainDETECT questionnaire used to identify the 
likelihood of a neuropathic pain component.36
 – Motion analysis (GaitSmart) at 24 months.28
 – Performance based tests at 24 months.29
 – Physical examination of contralateral knee, hips 
and hands.
Table 1 Baseline characteristics of the APPROACH cohort study Kellgren and Lawrence (grade)
Total
(n=297)
Utrecht
(n=153)
Leiden
(n=50)
À coruña
(n=43)
Oslo
(n=31)
Paris
(n=20)
P value
(ANOVA)
Age (years) 66.5 (7.1) 67.5 (6.5) 65.0 (7.0) 66.1 (6.9) 64.6 (8.9) 66.8 (8.8) 0.106
Female (%) 230 (77) 109 (71) 39 (78) 39 (91) 23 (74) 20 (100) 0.008
BMI (kg/m2) 28.1 (5.3) 27.1 (4.4) 27.4 (5.2) 31.3 (5.9) 28.7 (6.4) 29.3 (6.0) <0.001
KOOS
  Symptoms 69.5 (17.2) 75.2 (15.7) 65.5 (19.9) 61.9 (13.0) 63.7 (16.0) 62.0 (17.7) <0.001
  Pain 66.4 (18.8) 73.1 (17.1) 66.8 (19.1) 52.9 (12.7) 56.4 (17.1) 58.9 (19.9) <0.001
  Function 69.1 (19.0) 76.6 (16.5) 69.7 (20.9) 54.0 (10.0) 60.5 (17.3) 56.9 (19.3) <0.001
  Physical activity 42.9 (26.8) 52.1 (27.2) 38.0 (27.4) 28.5 (11.6) 31.8 (23.6) 33.8 (25.7) <0.001
  Quality of life 52.9 (20.7) 60.5 (19.0) 52.7 (18.9) 38.7 (12.5) 45.2 (19.1) 39.7 (27.8) <0.001
NRS pain (0–10)
  Index knee 4.6 (2.7) 3.8 (2.6) 4.3 (2.6) 6.7 (2.0) 5.4 (2.4) 5.7 (2.8) <0.001
KIDA
  Mean JSW index knee (mm) 5.5 (1.0) 5.6 (1.0) 5.4 (1.0) 5.3 (1.1) 5.2 (1.1) 5.3 (0.9) 0.158
  Minimum JSW index knee (mm) 2.5 (1.3) 2.7 (1.2) 2.5 (1.3) 2.3 (1.1) 1.8 (1.3) 2.6 (1.3) 0.008
KL grade 0.048
  Grade 0 51 (17%) 36 (24%) 6 (12%) 7 (16%) 0 (0%) 2 (10%)
  Grade 1 90 (30%) 41 (27%) 18 (36%) 14 (33%) 11 (36%) 6 (30%)
  Grade 2 88 (30%) 37 (24%) 14 (28%) 17 (40%) 11 (36%) 9 (55%)
  Grade 3 54 (18%) 30 (20%) 10 (20%) 3 (7%) 9 (29%) 2 (10%)
  Grade 4 10 (3%) 8 (5%) 1 (2%) 1 (2%) 0 (0%) 0 (0%)
Continuous variables are given as mean values, SD between brackets and categorical variables as total number, percentages between 
brackets. Differences between sites were evaluated using ANOVA followed by Tukey’s post hoc test. Statistically significant p- values are 
given in bold.
ANOVA, analysis of variance; APPROACH, Applied Public- Private Research enabling OsteoArthritis Clinical Headway; BMI, body mass 
index; JSW, joint space width; KIDA, knee image digital analysis; KL, Kellgren and Lawrence; KOOS, knee injury and osteoarthritis 
outcome score; NRS, Numeric Rating Scale.
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Table 2 Investigation schedule of the APPROACH cohort study
Screening BL 6 months 12 months 24 months
Medical history X X X X X
General physical examination
  Height X         
  Weight X X X X X
  Waist circumference   X X X X
  Blood pressure and pulse rate   X X X X
Joint examination
  ACR criteria for knee OA X         
  Knee   X X X X
  Hand   X X X X
  Hip   X X X X
Radiography
  Index knee X   X X X
  Contralateral knee   X     X
  Hands   X     X
CT- scan
  Index knee   X     X
  Whole Body Low Dose CT X     X
MRI- scan of index knee
  Thickness and volume of cartilage, denuded 
bone area
  X X X X
  MOAKS assessment   X X X X
  T2- mapping   X X     
Hand scan   X     X
Motion analysis   X X   X
Performance- based tests
  40- metre self- paced walk test   X X   X
  30 s chair stand- up test   X X   X
Questionnaires
  KOOS (pain, stiffness and function) X         
  KOOS   X X X X
  HOOS   X     X
  ICOAP index knee   X X X X
  ICOAP hip   X     X
  FIHOA   X     X
  Pain NRS index knee X X X X X
  Pain NRS other joints X X X X X
  PainDETECT   X X X X
  SF-36   X X X X
  One month pain diary   X X X X
Biological samples
  Serum   X X X X
  Plasma   X       
  DNA/RNA   X     X
  Urine   X X X X
ACR, American College of Rheumatology; APPROACH, Applied Public- Private Research enabling OsteoArthritis Clinical Headway; BL, baseline; FIHOA, 
Functional Index for Hand Osteoarthritis; HOOS, Hip disability and Osteoarthritis Outcome Score; ICOAP, Intermittent and Constant OsteoArthritis Pain; 
KOOS, Knee Injury and Osteoarthritis Outcome Score; MOAKS, MRI osteoarthritis knee score; NRS, Numeric Rating Scale; OA, osteoarthritis; SF-36, Short 
Form 36.
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 ► Optional systemic biochemical (bio)markers
 – Epigenetic, genomic, transcriptomic, proteom-
ic, lipidomic and metabolomic markers (to be 
defined).
 ► General clinical data
 – History and type of knee traumatism and surgery.
 – Smoking habits.
 – Menopausal status.
 – Concomitant OA treatment.
 ► Advanced parameters
 – Bone shape analysis on radiographs of contralater-
al knee.
 – Subchondral bone analysis on radiographs of con-
tralateral knee.
 – Bone shape analysis of the hip on WBLDCT.
Statistical analysis
Statistical analyses of baseline data for the current 
manuscript were performed using SPSS Statistics V.25. 
For evaluation of differences between included and 
excluded patients t- tests were used. Analysis of vari-
ance was used to compare included patients of the five 
different centres. P values <0.05 were considered as 
statistically significant.
Future analysis plan: Statistical analyses will be in line 
with the objectives of the original project. At time of 
data analysis the best methods to address the aims of 
APPROACH will be defined as this systems medicine 
is a fast evolving field. The final analysis plan will be 
decided on before database lock. In an overview it will 
comprise:
Validation of the prediction model used in the inclu-
sion process: Model predictions of pain and structural 
progression will be compared with actual observed 
progression over 2- year follow- up.
Development and validation of a predictive model for 
OA progression: Baseline data and/or change over the 
first six months follow- up will be used to train and test 
(ML) models for OA progression. External validation 
of these models will be needed for implementation in 
practice.
Discovery and prediction of phenotypes/endotypes: 
The dataset will be explored by use of different statistical 
approaches to define subgroups with common charac-
teristics. Identified phenotypes/endotypes will be be 
selected in discussion with clinical experts and described 
and predicted in enough detail to be of use in practical 
OA diagnosis and patient selection.
Patient and public involvement statement
A patient council (PC) was instituted to ensure that 
patients are represented in APPROACH. The PC contrib-
uted to the design of the clinical study and with that 
helped shape the project with particular consideration 
for the interests of study participants. The PC will main-
tain close contact with the researchers throughout the 
project.
Findings to date
Figure 2 describes the probability of progression, as 
predicted by the second, uniform ML model using 
the screening visit data of all patients, those who were 
finally selected and those that were excluded. For mean 
predicted progression scores (confidence estimates) and 
results for separate centres see online supplementary file 
3.
Figure 2 Predicted progression scores of the approach participants. combined (A), pain (B) and structural (C) progression 
scores (confidence estimates) of the ranked (n=409), selected (n=314) and excluded (n=112) patients. Boxplots represent 
mean±IQR.
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Included versus excluded patients
Out of the 314 patients, 297 patients attended their base-
line visit and were included in the cohort. The remaining 
17 patients withdrew after initial selection or could not 
attend the baseline visit before the deadline. All presented 
baseline parameters were statistically significant different 
between included and excluded patients, except for age 
and mean JSW (table 3).
The inclusion process of the APPROACH cohort is 
considered successful. The dual assessment with the addi-
tional screening visit and a second ML has demonstrated 
the practical value of the chosen recruitment strategy. 
Although one might have expected higher probabilities 
of progression from the selection process, opportunities 
for further optimisation were limited due to a narrow 
time window and available corresponding data from 
the source cohorts. Nevertheless, results show a clear 
differentiation in baseline data of selected and excluded 
patients, with a predicted increased progression proba-
bility of the selected patients. In two years, the success of 
the approach, viz. the true progression of these patients 
will become clear. The predicted probabilities will not be 
100%, so we expect sufficient non- progressive patients, 
those anticipated with the lowest probabilities for progres-
sion, that will serve as controls.
Data from the 2- year longitudinal cohort will provide 
valuable insights into the relevance of conventional and 
novel clinical, imaging and biochemical markers. Changes 
of these markers over the first 6 months will likely extend 
the ability to predict the likelihood for OA progression 
at 12 and 24 months (either pain, structural or both 
pain and structural) and distinguish between different 
OA phenotypes. New markers to identify relevant OA 
phenotypes/endotypes based on imaging, locomotion 
and biochemical/omics methods will be developed and 
validated. This will enable classification of each knee 
OA patient on a phenotype- specific progression scale. 
Ultimately, the APPROACH cohort intends to provide a 
basis for phenotype tailored trials of potential DMOADs, 
decrease the required number of study subjects and trial 
duration, and therewith form the basis for personalised/
stratified medicine in OA.
Strengths and limitations
The APPROACH cohort is part of a larger consor-
tium, bringing together a highly qualified and multi-
disciplinary group of stakeholders in the form of a 
public–private partnership of engaged, knowledgeable 
and complementary industrial, academics and patient 
experts. The APPROACH cohort is unique in its selec-
tion process, recruiting patients from existing cohorts 
based on ML models with encouraging results of which 
the actual utility needs to be demonstrated at the end 
of the 2- year follow- up. The APPROACH cohort will 
provide 2- year follow- up data of 297 knee OA patients 
including conventional and novel, explorative, imaging, 
biochemical, clinical and demographic (bio)markers 
according to strict protocols for acquisition and evalu-
ation with the aim to identify phenotypes and develop 
predictive models for progression of these phenotypes. 
The relative limited 2- year follow- up allows translation 
of results to pragmatic trial design in the future. The 
main limitations of the study are the descriptive phase in 
which the study is at present and the still limited number 
of included patients related to the large number of 
outcome parameters.
Collaboration
Currently, the data is confidential and only accessible 
for the partners of IMI- APPROACH. After completion 
of the project, access rights have to be approved by the 
IMI- APPROACH Steering Committee. More information 
on the project can be obtained from the website: www. 
approachproject. eu.
Table 3 Screening characteristics of the total study 
population
Included
(n=297)
Excluded
(n=109)
P value
(t- test)
Age (years) 66.5 (7.1) 68.1 (7.7) 0.061
Female (%) 230 (77) 80 (71) 0.013
BMI (kg/m2) 28.1 (5.3) 26.4 (4.4) 0.003
Adapted KOOS*
  Stiffness 38.5 (21.6) 24.3 (18.5) <0.001
  Pain 31.3 (19.7) 17.7 (14.6) <0.001
  Function 32.9 (19.1) 19.6 (16.3) <0.001
  Total 33.1 (18.8) 19.6 (15.4) <0.001
NRS pain last week (0–10)
  Index knee 4.6 (2.8) 2.6 (2.2) <0.001
  Contralateral knee 2.8 (2.5) 1.6 (2.2) <0.001
KIDA
  Mean JSW index knee 
(mm)
5.5 (1.0) 5.5 (1.1) 0.700
  Minimum JSW index 
knee (mm)
2.5 (1.3) 2.1 (1.0) 0.001
KL grade (%) ND NA
  Grade 0 51 (17)   
  
  
  
  
  
  
  
  
  
  Grade 1 90 (30)
  Grade 2 88 (30)
  Grade 3 54 (18)
  Grade 4 10 (3)
Continuous variables are given as mean values, SD between 
brackets and categorical variables as total number, percentages 
between brackets. Differences between included and excluded 
patients were evaluated using t- tests and Χ2 test (gender).
*A number of KOOS questions was used, weighted to provide a 
score for stiffness, pain and function of 0 (most severe) to 100 
(no limitations).
BMI, body mass index; JSW, joint space width; KIDA, knee 
image digital analysis; KL, Kellgren and Lawrence; KOOS, Knee 
injury and Osteoarthritis Outcome Score; NA, not applicable; 
ND, not determined; NRS, Numeric Rating Scale.
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